Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Sangamo Therapeutics, Inc. , a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics , a wholly owned subsidiary of Eli Lilly and...
Mark Mcclung Eli Lilly Exchange Commission Sangamo Therapeutics Inc Sangamo Therapeutics Prevail Therapeutics
Source: marketscreener.com